Navigation Links
BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update
Date:10/31/2008

Peramivir was generally safe and well-tolerated at these dose levels.

Detailed results will be submitted to an upcoming medical meeting.

-- BioCryst reported top-line results from the completed Phase 2a trial of

BCX-4208 in subjects with moderate to severe plaque psoriasis were

consistent with interim findings. BCX-4208, a potent, rationally

designed, orally available purine nucleoside phosphorylase inhibitor,

met its primary endpoint of safety and tolerability and displayed

dose-dependant reductions in peripheral blood lymphocyte counts. The

pharmacokinetic and pharmacodynamic results suggest that BCX-4208 may

have utility in diseases dependant on T-cells, B-cells or uric acid.

The Phase 2a results have been accepted for presentation at the 50th

American Society of Hematology Annual Meeting and Exposition (ASH),

which will be held in San Francisco, December 6-9, 2008.

-- The forodesine HCl pivotal trial in cutaneous T-cell lymphoma (CTCL)

continues to enroll subjects with CTCL stages IIB through IVA who have

failed three systemic therapies. The multinational study is evaluating

once daily oral forodesine HCL treatment and is being conducted in

accordance with a Special Protocol Assessment agreement between the U.S.

Food and Drug Administration and BioCryst. A laboratory study of

forodesine HCl in leukemia cells has been accepted for presentation at

ASH.

Conference Call and Web cast

BioCryst's management team will host a conference call and Web cast on Friday, October 31, 2008, at 8:30 a.m. Eastern Time to discuss the financial results and recent developments within the Company's programs. To participate in the conference call, please dial 1-800-860-2442 (United States) or 1-412-858-4600 (International). No passcode is needed for the call. The Web ca
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
2. BioCryst Pharmaceuticals To Announce Third Quarter 2008 Financial Results On October 31, 2008
3. BioCryst to Present at the JMP Healthcare Focus Conference
4. BioCryst to Present at UBS 2008 Global Life Sciences Conference
5. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
6. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
7. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
8. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
9. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
10. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
11. BioCryst to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; ... proprietary technologies and products for advanced microarray diagnostics, today ... fiscal quarter ended March 31, 2015. ... with our existing customers and to develop new opportunities," ... SQI. "The delivery of a fully automated sqidlite™ system ...
(Date:5/21/2015)... Francisco, CA (PRWEB) May 21, 2015 ... sequencing, has announced a partnership with PicnicHealth, a ... for patients. Participants diagnosed with Inflammatory Bowel Disease ... well as a complementary uBiome research kit. Both ... 2014. , For more information ...
(Date:5/21/2015)... 2015  CytRx Corporation (NASDAQ: CYTR ), ... oncology, today announced positive updated results from its ... the treatment of unresectable glioblastoma multiforme (GBM), a ... trial is designed to investigate the preliminary efficacy ... have progressed following prior treatment with surgery, radiation ...
(Date:5/21/2015)... Tunnell Consulting, Inc. today ... senior statistician and Principal, a position to which she ... management and analysis of complex and large data sets ... “We’re delighted to have Julia join the Tunnell team ... Dr. Philippe Cini, Group Vice President and leader of ...
Breaking Biology Technology:SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2
... June 17 MedPredict has published a,new report ... and,biotech companies with a stake in the market ... report, entitled "Thought Leader Insight &,Analysis: Alzheimer,s Disease," ... of physician thought leaders actively involved in ongoing,research., ...
... June 17 , - First World Allergy ... Increase in Allergies and Allergic Diseases, The ... Report on,the extent of allergy and chronic respiratory ... called for immediate collaboration to tackle the current,escalation ...
... Biomarker ... Industry, PHILADELPHIA and LONDON, June 17 ... for,businesses and professionals, announced today the launch of,BIOMARKERcenter, ... solution will be the first to provide the,pharmaceutical ...
Cached Biology Technology:Thought Leaders Discuss Positive Outlook for Bapineuzumab in Alzheimer's Disease in MedPredict Report 2World Allergy Organization Highlights Global Allergy Impact 2Thomson Reuters Launches New Biomarkers Solution 2
(Date:5/19/2015)... 19, 2015 Research ... addition of the  "Genetic Testing Market Outlook ... http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic Testing ... of the current and future genetic testing ... their working principles and types are covered ...
(Date:5/14/2015)... NEW YORK , May 14, 2015 ... specializing in identity verification and online remote ... Instructure, a software-as-a-service (SaaS) company and creator ... Shared customers of the two companies will ... Proctortrack in Canvas. As a ...
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... Australia, the United Kingdom and United States, including University of ... tactics, such as assisted migration, in the face of the ... policy ideas in a paper published July 18 in the ... that both the rapid rate of climate change and the ...
... as they evolve, biologists have unearthed several interesting patterns. ... members of a taxonomic group -- such as the ... elephant are often thousands or millions of times ... time two SFI researchers explain these patterns within an ...
... a close relative of the toadfish, doesn,t need good looks to ... nest for his potential partner, he calls to nearby females by ... buoyancy. The sound he makes is not a song or a ... a ballad. Female midshipman find it very alluring, and they only ...
Cached Biology News:Global warming experts recommend drastic measures to save species 2Predicting the distribution of creatures great and small 2When fish talk, scientists listen 2
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
Anti-ZFP-38/RU49 Family: Zinc Finger Peptide Sequence: SVKVEDKDFPSTCSKK...
UltraPure DNase/RNase-Free Distilled Water is designed for use in all molecular biology applications. It is 0.1-m membrane-filtered and tested for DNase and RNase activity....
...
Biology Products: